JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Tebipenem is an orally available carbapenem antibiotic. Tebipenem is active against a panel of clinical isolates from a variety of bacterial species (MIC50s ≤ 0.0039 ~ 8 µg/ml), including methicillin-resistant strains of Staphylococcus aureus (S. aureus) and Staphylococcus epidermidis (S. epidermidis), as well as penicillin-resistant Streptococcus pneumoniae (S. pneumonia). Tebipenem also inhibits β-lactamase in a time- and concentration-dependent manner. Tebipenem pivoxil, a derivative of tebipenem, has been under development as the first orally available carbapenem antibiotic for the treatment of respiratory and otolaryngological infections caused by drug-resistant S. pneumonia in pediatric patients.
References:
1. Hazra S, Xu H, Blanchard JS. Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry, 2014, 53(22): 3671-3678.
2. Fujimoto K, Takemoto K, Hatano K, et al. Novel carbapenem antibiotics for parenteral and oral applications: in vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animals. Antimicrobial Agents and Chemotherapy, 2013, 57(2): 697-707.
Animal models
A mouse model of penicillin-resistant S. pneumoniae infection
Dosage form
0.32 ~ 3.2 mg/kg
Administered intravenously thrice daily 1 day and 2 days after infection
Applications
Tebipenem dose-dependently decreased the number of colony forming units (CFUs) in the lungs of infected mice.
Note
The technical data provided above is for reference only.